
|Articles|January 1, 2003
Systemic retinoid chemoprophylaxis causes frequent adverse events for immunosuppressed transplant patients with advanced SCC
Chicago -- Although published clinical trial results suggest systemic retinoid therapy administered for skin cancer chemoprevention in immunosuppressed organ transplant recipients is well tolerated despite causing frequent adverse events,
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Transformative Advances This Year and Beyond
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
5


















